The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-α production in whole blood from COPD patients
Chronic obstructive pulmonary disease (COPD) is a common, progressive respiratory disease that causes great morbidity and mortality despite treatment. Tumor necrosis factor α (TNF-α) plays a central role as a pro-inflammatory cytokine in COPD. TNF-α release is markedly inhibited by phosphodiesterase...
Gespeichert in:
Veröffentlicht in: | Pulmonary pharmacology & therapeutics 2005-01, Vol.18 (1), p.49-54 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Chronic obstructive pulmonary disease (COPD) is a common, progressive respiratory disease that causes great morbidity and mortality despite treatment. Tumor necrosis factor α (TNF-α) plays a central role as a pro-inflammatory cytokine in COPD. TNF-α release is markedly inhibited by phosphodiesterase type 4 (PDE4) inhibitors that have proven efficacious in COPD clinical trials. The aim of this study was to compare the in vitro activities of the novel selective PDE4 inhibitors CI-1044 compared to well-known PDE4 inhibitors, rolipram and cilomilast, and to the glucocorticoid dexamethasone at reducing lipopolysaccharide (LPS)-induced TNF-α release in whole blood from COPD patients and healthy subjects. In the whole blood from COPD patients pre-incubation with PDE4 inhibitors or dexamethasone resulted in a dose-dependent inhibition of LPS-induced TNF-α release with IC
50 values of 1.3±0.7, 2.8±0.9
μM, higher to 10
μM and lesser than 0.03
μM for CI-1044, rolipram, cilomilast and dexamethasone, respectively. We observed a similar inhibition in the whole blood from healthy volunteers with, however, higher IC
50 values. These results indicate that CI-1044 inhibits in vitro LPS-induced TNF-α release in whole blood from COPD patients better than rolipram and cilomilast and suggested that it could be a useful anti-inflammatory therapy in COPD. |
---|---|
ISSN: | 1094-5539 1522-9629 |
DOI: | 10.1016/j.pupt.2004.09.031 |